[go: up one dir, main page]

MX2015012893A - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. - Google Patents

Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Info

Publication number
MX2015012893A
MX2015012893A MX2015012893A MX2015012893A MX2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A MX 2015012893 A MX2015012893 A MX 2015012893A
Authority
MX
Mexico
Prior art keywords
dengue
virus
compositions
dengue virus
den
Prior art date
Application number
MX2015012893A
Other languages
English (en)
Other versions
MX374519B (es
Inventor
Dan T Stinchcomb
Jill A Livengood
Claire Kinney
Richard M Kinney
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2015012893A publication Critical patent/MX2015012893A/es
Publication of MX374519B publication Critical patent/MX374519B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del dengue vivos atenuados. En ciertas modalidades, la composición puede incluir, pero no se limita a una composición tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o más serotipos del virus del dengue, tales como las construcciones del virus dengue-1 (DEN-1), el virus dengue-2 (DEN-2), los virus dengue-3 (DEN-3) o dengue-4 (DEN-4). En otras modalidades, en una composición para generar una vacuna contra una o más construcciones de virus del dengue que pueden o no ser subsecuentemente pasadas a células de mamíferos.
MX2015012893A 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. MX374519B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
PCT/US2014/024603 WO2014150939A2 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (2)

Publication Number Publication Date
MX2015012893A true MX2015012893A (es) 2016-04-04
MX374519B MX374519B (es) 2025-03-06

Family

ID=50678274

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2015012893A MX374519B (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000353A MX2023000353A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000353A MX2023000353A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Country Status (32)

Country Link
US (6) US9783579B2 (es)
EP (5) EP3539565B1 (es)
JP (2) JP6818548B2 (es)
KR (4) KR20250033325A (es)
CN (5) CN113637086B (es)
AR (4) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (3) CA3177574A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T5 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2933970T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I2 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (2) LT4129330T (es)
MX (5) MX374519B (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NO (1) NO2023026I1 (es)
NZ (1) NZ630869A (es)
PE (2) PE20211814A1 (es)
PH (1) PH12015502120B1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913435TA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI733646B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374519B (es) 2013-03-15 2025-03-06 Us Gov Health & Human Services Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
BR112018010690A8 (pt) * 2015-11-27 2019-02-26 The Chemo Sero Therapeutic Res Institute vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos
WO2017179017A1 (en) 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
AU2019335006B2 (en) 2018-09-05 2024-07-04 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
JP7648642B2 (ja) 2020-02-27 2025-03-18 タケダ ワクチン，インコーポレイテッド ウイルス調製物から宿主細胞ｄｎａを取り除く方法
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
JP2025507397A (ja) 2022-02-15 2025-03-18 タケダ ワクチン，インコーポレイテッド デング熱ワクチンバッチ混合プロセス
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4357464A1 (en) * 2022-10-20 2024-04-24 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69231570T2 (de) 1991-09-19 2001-06-21 Us Of America Represented By D Chimäre und/oder wachstumgehemmte Flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
ATE227584T1 (de) 1995-05-24 2002-11-15 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
CZ300172B6 (cs) 1997-02-28 2009-03-04 Acambis Inc. Chimerický živý, infekcní, oslabený virus, lécivopro prevenci nebo lécbu flavivirových infekcí s jeho obsahem a molekula nukleové kyseliny jej kódující
RU2208635C2 (ru) 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
DE29810020U1 (de) 1998-06-04 1998-09-24 Siemens AG, 80333 München Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
DE69934583T2 (de) 1998-06-04 2007-10-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
PT2278012E (pt) 2000-02-16 2015-11-30 Univ Mahidol Quimeras imunogénicas do vírus do dengue 2
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
ATE475706T1 (de) * 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
BRPI0614265A2 (pt) * 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AU2007285929B2 (en) * 2006-08-15 2013-09-05 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
ATE547425T1 (de) 2007-07-13 2012-03-15 Florida Gulf Coast University Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
BRPI0913012B1 (pt) * 2008-04-30 2021-12-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
EP2438198A4 (en) 2009-06-01 2014-05-14 Inviragen Inc COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2858668A1 (en) 2012-06-10 2015-04-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
KR20150036593A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
KR20200067938A (ko) 2012-07-24 2020-06-12 사노피 파스퇴르 백신 조성물
TW201428101A (zh) 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
US9878031B2 (en) * 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
MX374519B (es) * 2013-03-15 2025-03-06 Us Gov Health & Human Services Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
WO2017179017A1 (en) 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EA202090967A1 (ru) 2017-10-16 2020-08-12 Серум Инститьют Оф Индия Прайват Лимитед Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус, и процесс их приготовления
AU2019335006B2 (en) 2018-09-05 2024-07-04 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP3892737A1 (en) 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples

Also Published As

Publication number Publication date
UY35489A (es) 2014-10-31
CN113637694B (zh) 2024-11-12
KR20240014580A (ko) 2024-02-01
SG11201507460PA (en) 2015-10-29
JP6818548B2 (ja) 2021-01-20
AR095598A1 (es) 2015-10-28
AU2014235476B2 (en) 2019-05-16
NZ735336A (en) 2021-04-30
HRP20231581T1 (hr) 2024-03-15
BR112015023635A2 (pt) 2018-06-05
CN113637694A (zh) 2021-11-12
NZ630869A (en) 2017-11-24
CN105451763A (zh) 2016-03-30
NO2023026I1 (no) 2023-07-04
FI3539565T3 (fi) 2023-04-19
TW202144573A (zh) 2021-12-01
FR22C1064I2 (fr) 2024-12-13
MX2023000353A (es) 2023-02-13
BR122021015502A2 (pt) 2021-12-14
ES2933970T3 (es) 2023-02-15
KR102389908B1 (ko) 2022-04-26
DK4129330T5 (da) 2024-07-22
AU2019216724A1 (en) 2019-09-05
KR102626270B1 (ko) 2024-01-19
HK1220359A1 (zh) 2017-05-05
CN113637086B (zh) 2024-10-11
CA3177572A1 (en) 2014-09-25
EP2968516A2 (en) 2016-01-20
ECSP23013715A (es) 2023-04-28
HUS2300022I1 (hu) 2023-08-28
JP2019146594A (ja) 2019-09-05
TWI733646B (zh) 2021-07-21
BR122021015503A2 (pt) 2021-12-14
CN113637693A (zh) 2021-11-12
PL3539565T3 (pl) 2023-09-25
AU2019216724C1 (en) 2021-08-26
US11931399B2 (en) 2024-03-19
NL301223I2 (nl) 2023-07-26
KR20220054892A (ko) 2022-05-03
TWI894248B (zh) 2025-08-21
CN111778263A (zh) 2020-10-16
CN113637086A (zh) 2021-11-12
EP4129330B1 (en) 2023-09-06
CA2903231A1 (en) 2014-09-25
WO2014150939A3 (en) 2014-12-31
US12186363B2 (en) 2025-01-07
US10449231B2 (en) 2019-10-22
US20200061151A1 (en) 2020-02-27
US20220062375A1 (en) 2022-03-03
AR123702A2 (es) 2023-01-04
TW201516147A (zh) 2015-05-01
CN113637693B (zh) 2024-10-11
MX2019003602A (es) 2022-06-27
EP3689374B1 (en) 2022-11-02
US20140302088A1 (en) 2014-10-09
KR20250033325A (ko) 2025-03-07
DK4129330T3 (da) 2023-12-11
LTPA2024503I1 (es) 2024-03-25
US20170290884A1 (en) 2017-10-12
AU2014235476A1 (en) 2015-09-24
AR132009A2 (es) 2025-05-21
AU2019216724B2 (en) 2021-03-04
CA3177574A1 (en) 2014-09-25
KR20160002780A (ko) 2016-01-08
EP3539565B1 (en) 2023-01-11
JP2016513970A (ja) 2016-05-19
MX2023000349A (es) 2023-04-24
SG10201913387XA (en) 2020-02-27
PH12015502120A1 (en) 2016-01-25
BR112015023635A8 (pt) 2021-12-14
AR133264A2 (es) 2025-09-10
MY187796A (en) 2021-10-24
US9783579B2 (en) 2017-10-10
US20230181682A1 (en) 2023-06-15
CA3166063A1 (en) 2014-09-25
LT4129330T (lt) 2023-12-27
PE20160027A1 (es) 2016-01-28
CR20150569A (es) 2016-04-01
EP4129330A1 (en) 2023-02-08
EP2968516B1 (en) 2022-01-12
FIC20230021I1 (fi) 2023-06-27
SI4129330T1 (sl) 2024-02-29
PE20211814A1 (es) 2021-09-14
CN105451763B (zh) 2021-06-18
PH12015502120B1 (en) 2024-02-16
PT3539565T (pt) 2023-04-12
DOP2015000232A (es) 2016-02-29
EP3539565A1 (en) 2019-09-18
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
JP7050031B2 (ja) 2022-04-07
CA2903231C (en) 2025-12-09
KR102775714B1 (ko) 2025-03-06
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
MX374519B (es) 2025-03-06
EP4183411A1 (en) 2023-05-24
US20250018006A1 (en) 2025-01-16
TWI726312B (zh) 2021-05-01
MX2023000354A (es) 2023-02-13
SG10201913435TA (en) 2020-03-30
CN111778263B (zh) 2024-07-26
WO2014150939A2 (en) 2014-09-25
TW201945545A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
ECSP23013715A (es) Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
CO2018011355A2 (es) Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes
MX336687B (es) Tratamiento y prevencion de infecciones del virus del dengue.
MX2009010610A (es) Dominio de enlace especifico de especies cruzadas.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
MX2011008988A (es) Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CO6290702A2 (es) Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos
CO2021017772A2 (es) Virus del dengue atenuados
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
TH81521B (th) สเตบิไลเซอร์และองค์ประกอบวัคซีนซึ่งประกอบรวมด้วยฟลาวิไวรัสเชื้อมีชีวิตอ่อนฤทธิ์หนึ่งหรือมากกว่า

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted